Skip to main content

Treatment Clinical Trials for Rectal Cancer

Review the rectal cancer treatment clinical trials on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 26-47 of 47

No Surgery Trial / Two Dose-escalation Strategies
Status: Active
Location: UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas
FOLFOX, Botensilimab, and Balstilimab for the Treatment of Microsatellite Stable Localized Rectal Cancer before Surgery
Status: Active
Location: City of Hope Comprehensive Cancer Center, Duarte, California
Metronidazole to Reduce the Tumor Associated Bacteria of Rectal Adenocarcinoma in Patients Receiving Neoadjuvant Therapy
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
ctDNA-Directed Chemotherapy after Hepatectomy for the Treatment of Colorectal Liver Metastases
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Avutometinib, Defactinib and Cetuximab for the Treatment of Patients with Unresectable or Metastatic, Refractory Colorectal Cancer
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Combined Immunotherapy with Ipilimumab and Nivolumab or Nivolumab and Relatlimab and Radiation Therapy before Surgery for the Treatment of Sinonasal and Anorectal Melanoma
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Lenvatinib and Pembrolizumab for the Treatment of Unresectable, Locally Advanced, or Metastatic Anorectal Squamous Cell Cancer
Status: Active
Location: University of Chicago Comprehensive Cancer Center, Chicago, Illinois
Phase 2 Study of SR-8541A in Combination With Botensilimab and Balstilimab in Subjects With Refractory Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC)
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Indocyanine Green for Imaging of Solid Tumors during Surgery Compared to Standard of Care
Status: Active
Location: University of Pennsylvania/Abramson Cancer Center, Philadelphia, Pennsylvania
Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 Patients
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
Adaptive Radiation Therapy Boost for the Treatment of Rectal Cancer, The ARBOR Trial
Status: Active
Location: Fox Chase Cancer Center, Philadelphia, Pennsylvania
Neoadjuvant Chemotherapy Combined with Magnetic Resonance Image Guided Pelvic Adaptive Radiation Therapy for the Treatment of Locally Advanced Rectal Cancer, SMART TNT Study
Status: Active
Location: University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami, Florida
Short Course Radiation Therapy and Combination Chemotherapy for the Treatment of Stage II-III Rectal Cancer
Status: Active
Location: UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California
Chemotherapy with Radiation for the Treatment of Rectal Cancer
Status: Active
Location: UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas
Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
Status: Active
Location: Stanford Cancer Institute Palo Alto, Palo Alto, California
High Dose Rate Brachytherapy after Neoadjuvant Therapy to Avoid Major Surgery in Patients with Low-Lying Rectal Adenocarcinoma
Status: Active
Location: UCHealth University of Colorado Hospital, Aurora, Colorado
Time-Restricted Eating and Cancer: Clinical Outcomes, Mechanisms, and Moderators
Status: Active
Location: University of Alabama at Birmingham Cancer Center, Birmingham, Alabama
Physical Therapy and Coping Skills Training for Improving Women's Sexual Function after Pelvic Radiation
Status: Active
Location: Duke University Medical Center, Durham, North Carolina
A Study of Navicixizumab Monotherapy or in Combination in Patients With Select Advanced Solid Tumors
Status: Active
Location: University of Michigan Rogel Cancer Center, Ann Arbor, Michigan
Tislelizumab for the Treatment of Patients with Mismatch Repair Deficient Metastatic Colorectal Cancer or Stage II or III Rectal Cancer
Status: Approved
Location: Memorial Sloan Kettering Cancer Center, New York, New York
Encorafenib, Cetuximab, and Nivolumab in Treating Patients with Microsatellite Stable, BRAFV600E Mutated Unresectable or Metastatic Colorectal Cancer
Status: Temporarily Closed to Accrual
Location: M D Anderson Cancer Center, Houston, Texas
Universal Donor Natural Killer Cells in Combination with Aldesleukin and Vactosertib for the Treatment of Patients with Locally Advanced or Metastatic Colorectal, Gastric and Esophageal Cancers and Relapsed or Refractory Hematologic Cancers
Status: Temporarily Closed to Accrual
Location: Case Comprehensive Cancer Center, Cleveland, Ohio